retatrutide investigational drug triple hormone receptor agonist Medscape | Retatrutide, Eli Lilly's first-in-class agonist, delivered meaningful weight loss at 80 weeks in all doses in the Retatrutide 10mg — Triple Receptor

This combination activates lethal autophagy dependent on AMPK activation (AMPK kinase is activated by a decrease in intracellular ATP and a change in the ATP:AMP ratio), enhancing the sensitivity of radiation-resistant cells to cell death and efficacy of radiotherapy 29,77 (Figure 3)

Current guidelines advise discontinuation before conception due to unknown teratogenic risks

Precautions General The validity of diagnostic vitamin B12 or folic acid blood assays could be compromised by medications, and this should be considered before relying on such tests for therapy

*Percent daily value are based on a 2,000 calorie diet

In 2014, the drug was approved for weight loss under the brand name Saxenda

On Trustpilot, the picture is very different, with the company boasting a rating of 4.4 stars out of a possible 5 after more than 600 reviews